A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis

Inclusion criteria

• ✓. validated Investigator Global Assessment (vIGA) score ≥3 at Screening and Baseline
• ✓. Eczema Area and Severity Index (EASI) score ≥16 at both Screening and Baseline
• ✓. Peak Pruritus Numerical Rating Scale (PP-NRS) score of ≥4 at both Screening and Baseline
• ✓. ≥10% body surface area (BSA) of AtD involvement at both Screening and Baseline
• ✓. Documented recent history (within 6 months prior to Screening) of inadequate response to treatment with topical medications, or study participants for whom topical treatments are otherwise medically inadvisable (eg, due to important side effects or safety risks) and who are candidates for systemic therapy